Project Grant R01CA285336
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$628K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This federal Project Grant award, totaling $244,228.00, was provided by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will fund a research project led by the University of Texas MD Anderson Cancer Center to develop a functional proteomics approach for accurately mapping patient tumor samples to preclinical lung cancer models. The key objectives are to: 1) expand proteomic profiling of lung cancer patient-derived xenograft...
This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $160,330 to the University of Illinois to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human lung tumors. The researchers aim to introduce oncogenic mutations into primary human lung stem and progenitor cells, and then culture them as tumor organoids or xenograft them into immunodeficient mice. This work seeks to...
This $544,475 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to develop an in vitro cancer metastasis model system using decellularized organ-specific tissue (biomatrices) to study organ-specific cancer metastasis. The University of Texas Southwestern Medical Center, the awardee, hypothesizes that the biomatrices can recapitulate the organ microenvironment and enable the growth of organ-specific tumor colonies, which can be used to investigate...
This Project Grant award of $678,723 from the National Cancer Institute (NCI) under CFDA 93.395, the Cancer Treatment Research program, supports research on the regulation and clinical significance of programmed death ligand 1 (PD-L1) in lung cancer. The principal aims are to evaluate the clinical utility of PD-L1 and an associated E3 ligase enzyme in lung cancer diagnosis and prognosis (Aim 1), and to investigate the molecular mechanisms by which PD-L1 ubiquitination and trafficking impact...
This federal Cooperative Agreement award for $811,500.00 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to bridge the gap between bioinformatics and mathematical modeling for patient-specific tumor modeling. The project aims to merge bioinformatics software for analyzing single-cell and spatial multi-omics data with an agent-based modeling framework to simulate cell interactions in virtual tumor environments. Key objectives include refining a cell...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $119,172 to The Leland Stanford Junior University to conduct research aimed at "Harnessing Multi-Modal and Multi-Omics Data Integration to Decipher Therapeutic Response in Non-Small Cell Lung Cancer." The key objectives are to: (1) Identify clinically relevant spatial cellular architectures contributing to therapeutic response; (2) Develop an image-based digital cytometer to...